Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Short-term Investments (2018 - 2025)

Abeona Therapeutics (ABEO) has 10 years of Short-term Investments data on record, last reported at $124.2 million in Q3 2025.

  • For Q3 2025, Short-term Investments rose 32.2% year-over-year to $124.2 million; the TTM value through Sep 2025 reached $124.2 million, up 32.2%, while the annual FY2024 figure was $74.4 million, 96.97% up from the prior year.
  • Short-term Investments reached $124.2 million in Q3 2025 per ABEO's latest filing, up from $62.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $124.2 million in Q3 2025 and bottomed at $11.0 million in Q1 2022.
  • Average Short-term Investments over 5 years is $49.6 million, with a median of $44.8 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: tumbled 85.34% in 2021, then skyrocketed 294.42% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $12.1 million in 2021, then surged by 213.85% to $37.9 million in 2022, then dropped by 0.47% to $37.8 million in 2023, then skyrocketed by 96.97% to $74.4 million in 2024, then skyrocketed by 67.06% to $124.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $124.2 million in Q3 2025, $62.0 million in Q2 2025, and $68.2 million in Q1 2025.